Hara Oyedeji, DNP, PMHNP-BC

Patients weigh trade-offs differently than clinicians do, and they arrive having already consulted the internet. The panel examines what to honor in shared decision-making without sacrificing the evidence.

The field finally has new targets after decades anchored to monoamines. Dr. DeBattista explains why he welcomes them while predicting, from experience, that most of them will not work out.

Stopping an antidepressant is as much a clinical act as starting one, and it is often done badly. Dr. Clayton reviews when to discontinue and when a slower taper is warranted.

A patient who is better but not well presents the field's most common decision. The panel works through the thresholds that separate optimizing, switching, combining, and augmenting.

Two decades after a landmark STAR*D trial recalibrated expectations, Dr. DeBattista argues the standard of care has barely moved, and that measurement-based care remains the underused lever.

The side effect that stops the drug is usually the one nobody warned about. The panel works through what belongs in the first conversation and how often to reassess for suicidality.

Start low and go slow collides with therapeutic urgency more often than guidelines admit. Dr. DeBattista walks through the hepatic, renal, and cytochrome considerations that force a prescriber's hand.

The weeks spent waiting for an antidepressant to work are a window for dropout and risk. The panel debates who earns a faster-acting option up front and what monitoring that choice requires.

A significant improvement on a rating scale can still leave a patient unable to function. Dr. DeBattista explains how he defines meaningful improvement and when non-response should change the plan.

One approval took decades and a stack of complete response letters. Dr. Clayton reviews where these two agents fit, what their trials showed, and why patient preference should drive the choice.

An oral glutamatergic option without the logistics of ketamine. Dr. Shirikjian walks through the trial program, the week-one separation, and the mechanism she had to unlearn to understand.

Older antidepressants did not get less effective, only less convenient. Dr. Clayton explains where tricyclics and MAOIs still belong, and when combining psychotherapy with medication outperforms either alone.

Most depression in this country is never treated by a psychiatrist. The panel maps which parts of the journey primary care can own, where handoffs break down, and what safety demands first.

The imaging evidence is associational, not causal. The panel weighs whether that is reason enough for a skeptical colleague to treat depression earlier, and how anxiety complicates the picture.

Fatigue and poor sleep send patients to primary care, but a CBC and a thyroid panel will not find depression. The panel examines what actually separates major depression from its mimics.

Clinicians outline ways to boost schizophrenia outcomes: team-and-family collaboration, early detection, medication access, measurement-based care.

New rapid-acting and long-acting injectables help bridge hospital-to-community care, cutting post-discharge nonadherence and relapse risk.

Depression rarely arrives named. The panel opens on the presentations that mask it, the risk factors worth flagging in primary care, and the lag between first symptom and adequate treatment.

Clinicians weigh telepsychiatry for schizophrenia, urge early long-acting injectables, and reveal tips on samples, coupons, and prior authorizations.

Inside the ED psychiatric crisis pathway: rapid evaluation, safety triage, long-acting injectables,

Discover how coordinated schizophrenia care teams—clinicians, social supports, and peers—improve communication, housing, work, and quality of life.

Clinicians track relapse risk in schizophrenia by spotting functional decline, paranoia, missed care, and triggers, using family check-ins, brief scales, and labs.

Therapeutic drug monitoring clarifies adherence and plasma levels, while long-acting injectables and patches reduce variability and support patient-centered benefit-risk decisions.

Clinicians weigh oral, LAI and transdermal antipsychotics, urging early use, adherence focus, and side-effect education to optimize outcomes.

This episode, titled "Integrating Novel Mechanisms into Schizophrenia Treatment Practice," features panelist Mark Jankelow discussing the practical clinical considerations surrounding a novel muscarinic agent.

Explore 2024’s xanomeline–trospium: M1/M4 muscarinic therapy for schizophrenia, easing EPS and metabolic risks while raising GI concerns.

Explore how the asenapine transdermal patch helps schizophrenia care with steadier dosing, fewer side effects, and new options beyond sublingual pills.

Clinicians empower schizophrenia patients with shared decisions and flexible treatment options—oral, long-acting injectable, or transdermal—to improve adherence, trust, and remission potential.

Clinicians weigh diagnosis clarity, side effects, and adherence when choosing antipsychotic formulations, often starting oral therapy then switching to long-acting injectables.

Explore today’s schizophrenia treatments, comparing first-, second-, and newer antipsychotics, clozapine’s role, and how side effects and adherence drive medication choices.